title: Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations.
abstract: Intravenous iron, used for the treatment of anemia in chronic renal failure and other diseases, represents a possible source of free iron in tissue cells, particularly in the liver. In this study we examined the effect of different sources of intravenous iron (IVI) on the labile iron pool (LIP) which represents the nonferritin-bound, redox-active iron that is implicated in oxidative stress and cell injury. Furthermore, we examined the role of the LIP for the synthesis of ferritin. We used HepG2 cells as a well known model for hepatoma cells and monitored the LIP with the metal-sensitive fluorescent probe, calcein-AM, the fluorescence of which is quenched on binding to iron. We showed that steady state LIP levels in HepG2 cells were increased transiently, up to three-fold compared to control cells, as an adaptive response to long-term IVI exposure. In relation to the amount of iron in the LIP, the ferritin levels increased and the iron content of ferritin decreased. As any fluctuation in the LIP, even when it is only transient (e.g. after exposure to intravenous iron in this study), may result either in impairment of synthesis of iron containing proteins or in cell injury by pro-oxidants. Such findings in nonreticuloendothelial cells may have important implications in the generation of the adverse effects of chronic iron exposure reported in dialysis patients.
authors.affiliation: Department of Medical Chemistry, University of Vienna, Austria.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Sturm
authors.forename: Hans
authors.initials: H
authors.lastname: Goldenberg
authors.forename: Barbara
authors.initials: B
authors.lastname: Scheiber-Mojdehkar
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000378:metabolism*; D005290:Ferric Compounds / Q000008:administration & dosage*; D005293:Ferritins / Q000032:analysis / Q000096:biosynthesis; D005452:Fluoresceins / Q000737:chemistry / Q000378:metabolism; D005453:Fluorescence; D006801:Humans; D006835:Hydrazones / Q000494:pharmacology; D007275:Injections, Intravenous; D007501:Iron / Q000378:metabolism* / Q000494:pharmacology*; D007502:Iron Chelating Agents / Q000494:pharmacology; D008113:Liver Neoplasms / Q000378:metabolism*; D018384:Oxidative Stress; D014407:Tumor Cells, Cultured
chemical_list: D005290:Ferric Compounds; D005452:Fluoresceins; D006835:Hydrazones; D007502:Iron Chelating Agents; D005293:Ferritins; D007501:Iron